ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2016

Aug 23, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2016-08-19

Reporting Person: Bencich John (CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-19	Common Stock	M	5000	$0.00	Acquired	5000	Direct
2016-08-19	Common Stock	S	1380	$0.57	Disposed	9484	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-19	Restricted Stock Unit (RSU)	$	M	5000	Disposed		Common Stock (5000)	Direct

Footnotes

F1: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.

F2: Represents shares of common stock that have been sold by the issuer to satisfy the tax liability in connection with the settlement of RSUs.

F3: Each restricted stock unit (RSU) represents a contingent right to receive one share of the issuer's common stock at settlement.

F4: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of: (i) each anniversary of August 12, 2014 and (ii) the first day thereafter during which the issuer's trading window is open.

F5: The RSUs expire 30 days from the date they vest.